Sabina Signoretti
#151,806
Most Influential Person Now
Researcher
Sabina Signoretti's AcademicInfluence.com Rankings
Sabina Signoretticomputer-science Degrees
Computer Science
#8051
World Rank
#8470
Historical Rank
Machine Learning
#3184
World Rank
#3223
Historical Rank
Artificial Intelligence
#3488
World Rank
#3538
Historical Rank
Database
#5095
World Rank
#5292
Historical Rank
Download Badge
Computer Science
Sabina Signoretti's Degrees
- PhD Computer Science University of Milan
- Masters Computer Science University of Milan
Similar Degrees You Can Earn
Why Is Sabina Signoretti Influential?
(Suggest an Edit or Addition)Sabina Signoretti's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- The landscape of somatic copy-number alteration across human cancers (2010) (3297)
- The Immune Landscape of Cancer (2018) (2766)
- Comprehensive molecular characterization of clear cell renal cell carcinoma (2013) (1724)
- Oncogenic Signaling Pathways in The Cancer Genome Atlas (2018) (1646)
- Comprehensive analyses of tumor immunity: implications for cancer immunotherapy (2016) (1364)
- Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) (1360)
- High-throughput oncogene mutation profiling in human cancer (2007) (1041)
- Renal cell carcinoma (2017) (1023)
- Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. (2016) (931)
- Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. (2005) (857)
- Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma (2018) (772)
- Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. (2015) (727)
- Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis (2008) (646)
- p63 is a prostate basal cell marker and is required for prostate development. (2000) (629)
- Pathogenic Germline Variants in 10,389 Adult Cancers (2018) (501)
- The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (2018) (480)
- SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression (2011) (471)
- Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) (471)
- Loss of the Lkb1 tumour suppressor provokes intestinal polyposis but resistance to transformation (2002) (454)
- Forkhead Transcription Factors Are Critical Effectors of Cell Death and Cell Cycle Arrest Downstream of PTEN (2000) (452)
- Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. (2014) (445)
- Carbonic Anhydrase IX Expression Predicts Outcome of Interleukin 2 Therapy for Renal Cancer (2005) (405)
- Her-2-neu expression and progression toward androgen independence in human prostate cancer. (2000) (392)
- Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney. (2009) (392)
- Targeting lactate dehydrogenase--a inhibits tumorigenesis and tumor progression in mouse models of lung cancer and impacts tumor-initiating cells. (2014) (386)
- Patterns of somatic structural variation in human cancer genomes (2020) (377)
- A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis (2019) (356)
- Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene. (2011) (356)
- Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. (2009) (352)
- Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors (2018) (342)
- Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma (2020) (324)
- The isopeptidase USP2a regulates the stability of fatty acid synthase in prostate cancer. (2004) (323)
- On-target efficacy of a HIF-2α antagonist in preclinical kidney cancer models (2016) (313)
- Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. (2002) (312)
- Genomic sequencing of colorectal adenocarcinomas identifies a recurrent VTI1A-TCF7L2 fusion (2011) (298)
- The requirement for cyclin D function in tumor maintenance. (2012) (292)
- Loss or altered subcellular localization of p27 in Barrett's associated adenocarcinoma. (1998) (290)
- Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. (2014) (262)
- Landscape of tumor-infiltrating T cell repertoire of human cancers (2016) (250)
- VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400 (2008) (247)
- PD-L1 expression in nonclear-cell renal cell carcinoma. (2014) (246)
- BCR/ABL Regulates Expression of the Cyclin-dependent Kinase Inhibitor p27Kip1 through the Phosphatidylinositol 3-Kinase/AKT Pathway* (2000) (245)
- Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma. (2015) (244)
- Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma (2015) (239)
- Primary cutaneous marginal zone B-cell lymphoma: a recently described entity of low-grade malignant cutaneous B-cell lymphoma. (1997) (233)
- Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. (2014) (222)
- LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer (2009) (221)
- Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model (2016) (217)
- Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. (2013) (212)
- Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate (2019) (209)
- Correlation of PD-L1 Tumor Expression and Treatment Outcomes in Patients with Renal Cell Carcinoma Receiving Sunitinib or Pazopanib: Results from COMPARZ, a Randomized Controlled Trial (2014) (208)
- Comprehensive molecular characterization of mitochondrial genomes in human cancers (2017) (197)
- Role of the Cdc25A phosphatase in human breast cancer. (2000) (197)
- An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer (2018) (195)
- Androgen-Induced Differentiation and Tumorigenicity of Human Prostate Epithelial Cells (2004) (193)
- p63-expressing cells are the stem cells of developing prostate, bladder, and colorectal epithelia (2013) (192)
- Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context (2018) (188)
- The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma (2010) (181)
- A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis (2014) (175)
- Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma (2016) (169)
- A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. (2008) (164)
- Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine (2016) (160)
- p63 regulates commitment to the prostate cell lineage. (2005) (153)
- Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. (2016) (148)
- Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53-Null Tumors (2013) (148)
- Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. (2002) (145)
- pVHL suppresses kinase activity of Akt in a proline-hydroxylation–dependent manner (2016) (144)
- Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1 (2011) (143)
- Tumor and immune reprogramming during immunotherapy in advanced renal cell carcinoma (2021) (142)
- FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. (2010) (137)
- SQSTM1 is a pathogenic target of 5q copy number gains in kidney cancer. (2013) (137)
- Reciprocal Effects of STAT5 and STAT3 in Breast Cancer (2009) (136)
- A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer (2013) (135)
- Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. (2007) (134)
- Metabolomic adaptations and correlates of survival to immune checkpoint blockade (2019) (130)
- Loss of Hypoxia-Inducible Factor Prolyl Hydroxylase Activity in Cardiomyocytes Phenocopies Ischemic Cardiomyopathy (2010) (130)
- Progressive immune dysfunction with advancing disease stage in renal cell carcinoma. (2021) (129)
- Lrf suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion (2013) (128)
- Identification of luminal breast cancers that establish a tumor-supportive macroenvironment defined by proangiogenic platelets and bone marrow-derived cells. (2012) (128)
- The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma (2014) (127)
- Does arterial spin-labeling MR imaging-measured tumor perfusion correlate with renal cell cancer response to antiangiogenic therapy in a mouse model? (2009) (125)
- Diagnostic Utility of Immunohistochemical Staining for p63, a Sensitive Marker of Prostatic Basal Cells (2002) (125)
- Safety and efficacy of in vivo gene transfer into the porcine heart with replication-deficient, recombinant adenovirus vectors. (1996) (124)
- Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. (2000) (120)
- A Working Group Classification of Focal Prostate Atrophy Lesions (2006) (118)
- The Role of Mammalian Target of Rapamycin Inhibitors in the Treatment of Advanced Renal Cancer (2007) (115)
- Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms (2018) (114)
- PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells (2015) (113)
- Intermediate basal cells of the prostate: In vitro and in vivo characterization (2003) (113)
- Stabilization of β-catenin induces lesions reminiscent of prostatic intraepithelial neoplasia, but terminal squamous transdifferentiation of other secretory epithelia (2002) (110)
- Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma (2020) (109)
- Erratum : The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (Cell Reports (2018) 23(1) (313–326.e5) (S2211124718304364) (10.1016/j.celrep.2018.03.075)) (2018) (103)
- Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. (2017) (98)
- The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC). (2010) (96)
- Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival. (2018) (96)
- Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. (2010) (94)
- Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity. (2017) (94)
- BRAF mutations in metanephric adenoma of the kidney. (2012) (93)
- Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear‐cell renal cell carcinoma receiving vascular endothelial growth factor‐targeted therapy (2010) (91)
- Androgen-driven prostate epithelial cell proliferation and differentiation in vivo involve the regulation of p27. (2001) (87)
- Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. (2005) (87)
- p63 in prostate biology and pathology (2008) (86)
- Androgen-dependent regulation of Her-2/neu in prostate cancer cells. (2006) (86)
- The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma. (2018) (86)
- Combination of radiofrequency ablation with antiangiogenic therapy for tumor ablation efficacy: study in mice. (2007) (85)
- Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features. (2019) (84)
- The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non–Clear Cell Renal Cell Carcinoma (2018) (83)
- Whole Exome Sequencing Identifies TSC1/TSC2 Biallelic Loss as the Primary and Sufficient Driver Event for Renal Angiomyolipoma Development (2016) (80)
- Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma (2020) (79)
- Obligate Roles for p16Ink4a and p19Arf-p53 in the Suppression of Murine Pancreatic Neoplasia (2002) (78)
- The Role of Aberrant VHL/HIF Pathway Elements in Predicting Clinical Outcome to Pazopanib Therapy in Patients with Metastatic Clear-Cell Renal Cell Carcinoma (2013) (78)
- Resistance of Renal Cell Carcinoma to Sorafenib Is Mediated by Potentially Reversible Gene Expression (2011) (77)
- Vulnerabilities of PTEN-TP53-deficient prostate cancers to compound PARP-PI3K inhibition. (2014) (77)
- Programmed death ligand-1 expression in adrenocortical carcinoma: an exploratory biomarker study (2015) (76)
- Liposomal doxorubicin increases radiofrequency ablation-induced tumor destruction by increasing cellular oxidative and nitrative stress and accelerating apoptotic pathways. (2010) (76)
- Detection of clonal T-cell receptor gamma gene rearrangements in paraffin-embedded tissue by polymerase chain reaction and nonradioactive single-strand conformational polymorphism analysis. (1999) (75)
- Phase 2 trial of sunitinib and gemcitabine in patients with sarcomatoid and/or poor‐risk metastatic renal cell carcinoma (2015) (74)
- Estrogen Receptor in Prostate Cancer (2001) (73)
- Perfusion MDCT enables early detection of therapeutic response to antiangiogenic therapy. (2008) (71)
- Transition from In Situ to Invasive Testicular Germ Cell Neoplasia is Associated with the Loss of p21 and Gain of mdm-2 Expression (2001) (69)
- Phosphorylation of ETS1 by Src family kinases prevents its recognition by the COP1 tumor suppressor. (2014) (68)
- Potential Histologic and Molecular Predictors of Response to Temsirolimus in Patients with Advanced Renal Cell Carcinoma (2007) (64)
- Anti-S1P Antibody as a Novel Therapeutic Strategy for VEGFR TKI-Resistant Renal Cancer (2015) (63)
- irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial (2019) (62)
- Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients (2013) (62)
- Reduced tumor growth with combined radiofrequency ablation and radiation therapy in a rat breast tumor model. (2005) (62)
- The glomuvenous malformation protein Glomulin binds Rbx1 and regulates cullin RING ligase-mediated turnover of Fbw7. (2012) (60)
- Renal Cancer Resistance to Antiangiogenic Therapy Is Delayed by Restoration of Angiostatic Signaling (2010) (60)
- Integrative molecular characterization of sarcomatoid and rhabdoid renal cell carcinoma (2020) (58)
- A constitutively activated form of the p110β isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice (2010) (57)
- Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET). (2013) (56)
- Primary effusion lymphoma in HIV‐infected patients with multicentric Castleman's disease (2001) (55)
- From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. (2021) (55)
- Melanocytic nevi of palms and soles: a histological study according to the plane of section. (1999) (54)
- Improved tumor destruction with arsenic trioxide and radiofrequency ablation in three animal models. (2006) (54)
- Chimeric antigen receptor T cells secreting anti-PD-L 1 antibodies more effectively regress renal cell carcinoma in a humanized mouse model (2016) (54)
- Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. (2013) (53)
- Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model. (2017) (52)
- Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors (2018) (51)
- Radiofrequency ablation combined with liposomal quercetin to increase tumour destruction by modulation of heat shock protein production in a small animal model (2011) (51)
- Modulation of epithelial neoplasia and lymphoid hyperplasia in PTEN+/- mice by the p85 regulatory subunits of phosphoinositide 3-kinase. (2005) (50)
- The KDM5A/RBP2 histone demethylase represses NOTCH signaling to sustain neuroendocrine differentiation and promote small cell lung cancer tumorigenesis (2019) (49)
- Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo (2015) (48)
- Integrative Analysis of 1q23.3 Copy-Number Gain in Metastatic Urothelial Carcinoma (2014) (48)
- Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model? (2010) (47)
- Estrogen receptor beta in prostate cancer: brake pedal or accelerator? (2001) (46)
- Opposing effects of androgen deprivation and targeted therapy on prostate cancer prevention. (2013) (46)
- Tumor Vascularity in Renal Masses: Correlation of Arterial Spin-Labeled and Dynamic Contrast-Enhanced Magnetic Resonance Imaging Assessments. (2016) (45)
- Risk of bilateral renal cell cancer. (2009) (45)
- Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma (2016) (45)
- Prostate stem cells: from development to cancer. (2007) (44)
- Collecting duct carcinoma of the kidney is associated with CDKN2A deletion and SLC family gene up-regulation (2016) (44)
- A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma (2019) (43)
- Renal Cell Carcinoma in the Era of Precision Medicine: From Molecular Pathology to Tissue-Based Biomarkers. (2018) (43)
- p63 Promotes Cell Survival through Fatty Acid Synthase (2009) (42)
- Sex differences in oncogenic mutational processes (2019) (41)
- Defining Cell Lineages in the Prostate Epithelium (2006) (40)
- PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN (2019) (40)
- Adult Renal Cell Carcinoma: A Review of Established Entities from Morphology to Molecular Genetics. (2015) (40)
- Tissue biomarkers in renal cell carcinoma: Issues and solutions (2009) (39)
- RNA-seq Reveals Aurora Kinase–Driven mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma (2014) (39)
- Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260). (2020) (38)
- Detection of TCR‐γ gene rearrangements in early mycosis fungoides by non‐radioactive PCR‐SSCP (2000) (38)
- Mammalian SWI/SNF Complex Genomic Alterations and Immune Checkpoint Blockade in Solid Tumors (2020) (38)
- Treatment selection for patients with metastatic renal cell carcinoma (2009) (38)
- KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1 (2020) (37)
- HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species (2019) (37)
- Orthotopic xenografts of RCC retain histological, immunophenotypic and genetic features of tumours in patients (2011) (36)
- GRK3 is essential for metastatic cells and promotes prostate tumor progression (2014) (36)
- The surgical treatment of pituitary adenomas in the eighth decade. (1999) (35)
- Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts (2013) (35)
- HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase (2017) (34)
- Carbonic Anhydrase IX (CAIX) expression predicts for renal cell cancer (RCC) patient response and survival to IL-2 therapy. (2004) (34)
- Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma (2018) (33)
- Whole-Exome Sequencing in Two Extreme Phenotypes of Response to VEGF-Targeted Therapies in Patients With Metastatic Clear Cell Renal Cell Carcinoma. (2016) (31)
- High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma (2011) (31)
- Intratumor Heterogeneity of Perfusion and Diffusion in Clear-Cell Renal Cell Carcinoma: Correlation With Tumor Cellularity. (2016) (31)
- The future of perioperative therapy in advanced renal cell carcinoma: how can we PROSPER? (2019) (29)
- Cytokeratin15-positive basal epithelial cells targeted in graft-versus-host disease express a constitutive antiapoptotic phenotype. (2007) (29)
- D-cyclins repress apoptosis in hematopoietic cells by controlling death receptor Fas and its ligand FasL. (2014) (29)
- Poor prognosis and advanced clinicopathological features of clear cell renal cell carcinoma (ccRCC) are associated with cytoplasmic subcellular localisation of Hypoxia inducible factor-2α. (2014) (28)
- LBA67 Phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients (Pts) with renal cell carcinoma (RCC) undergoing nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial (2022) (28)
- PD-L1 expression in primary clear cell renal cell carcinomas (ccRCCs) and their metastases. (2014) (28)
- Expression of T-Cell Exhaustion Molecules and Human Endogenous Retroviruses as Predictive Biomarkers for Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma (2020) (27)
- A Non-integrating Lentiviral Approach Overcomes Cas9-Induced Immune Rejection to Establish an Immunocompetent Metastatic Renal Cancer Model (2018) (27)
- Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma (2016) (25)
- Differential Expression of PD‐L1 in High Grade T1 vs Muscle Invasive Bladder Carcinoma and its Prognostic Implications (2017) (25)
- Suppression of CHK1 by ETS Family Members Promotes DNA Damage Response Bypass and Tumorigenesis. (2015) (24)
- Immunohistochemical staining for BRAF V600E supports the diagnosis of metanephric adenoma (2015) (24)
- PD-L 1 expression in nonclear-cell renal cell carcinoma (2014) (23)
- Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (22)
- Tissue-Based Research in Kidney Cancer: Current Challenges and Future Directions (2008) (22)
- Results of a phase II study of atezolizumab and bevacizumab in non-clear cell renal cell carcinoma (nccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (sccRCC). (2019) (21)
- Gene Transcript Quantitation by Real-Time RT-PCR in Cells Selected by Immunohistochemistry-Laser Capture Microdissection (2002) (21)
- Pml represses tumour progression through inhibition of mTOR (2011) (21)
- Development of a Histopathology Informatics Pipeline for Classification and Prediction of Clinical Outcomes in Subtypes of Renal Cell Carcinoma (2021) (20)
- Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma and its association with PD-L1 expression (2017) (20)
- Neutrophilic figurate erythema of infancy. (1997) (20)
- Innovations and challenges in renal cancer: Summary statement from the Third Cambridge Conference (2009) (19)
- Coding of smooth eye movements in three-dimensional space by frontal cortex (19)
- Hypoxia regulation of the cell cycle in malignant melanoma: putative role for the cyclin‐dependent kinase inhibitor p27Kip1 (2004) (19)
- ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma (2021) (19)
- PD-L1 expression in non-clear cell renal cell carcinoma. (2014) (19)
- MET as a Target in Papillary Renal Cell Carcinoma (2014) (18)
- Role of the Cdc 25 A phosphatase in human breast cancer (2000) (17)
- p63+ ureteric bud tip cells are progenitors of intercalated cells. (2017) (15)
- A phase 1 study of buparlisib and bevacizumab in patients with metastatic renal cell carcinoma progressing on vascular endothelial growth factor‐targeted therapies (2016) (15)
- Genomic investigation of etiologic heterogeneity: methodologic challenges (2014) (15)
- RET protein expression in papillary renal cell carcinoma. (2012) (15)
- Reciprocal Effects of STAT 5 and STAT 3 in Breast Cancer (2009) (14)
- Clonality of cutaneous B-cell infiltrates determined by microdissection and immunoglobulin gene rearrangement. (1999) (14)
- ΔNp63 (p40) expression in prostatic adenocarcinoma with diffuse p63 positivity. (2015) (14)
- PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143). (2019) (14)
- Carbonic anhydrase IX (CAIX) as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma (mccRCC) in patients (pts) receiving sorafenib: Analysis of a randomized controlled trial (TARGET). (2012) (13)
- Loss of LDAH associated with prostate cancer and hearing loss (2018) (13)
- A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes (2021) (13)
- Integrative clinical and molecular characterization of translocation renal cell carcinoma. (2022) (13)
- Carbonic anhydrase IX as a predictive biomarker of response to kidney cancer therapy (2008) (13)
- Pharmacogenomic Markers of Targeted Therapy Toxicity in Patients with Metastatic Renal Cell Carcinoma. (2016) (13)
- De novo pyrimidine synthesis is a targetable vulnerability in IDH mutant glioma (2022) (13)
- Atezolizumab plus bevacizumab in non-clear cell renal cell carcinoma (NccRCC) and clear cell renal cell carcinoma with sarcomatoid differentiation (ccRCCsd): Updated results of activity and predictive biomarkers from a phase II study. (2019) (13)
- Summary from the First Kidney Cancer Research Summit, September 12-13, 2019: A Focus on Translational Research. (2020) (13)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts (2016) (12)
- A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC). (2017) (12)
- Prognostic significance and immune correlates of CD73 expression in renal cell carcinoma (2020) (12)
- Young investigator challenge: Application of cytologic techniques to circulating tumor cell specimens: Detecting activation of the oncogenic transcription factor STAT3 (2015) (12)
- Integrated genomic correlates of response to PD-1 inhibitor nivolumab in metastatic renal cell carcinoma (mRCC). (2016) (11)
- Phase II Study of Nivolumab and Salvage Nivolumab/Ipilimumab in Treatment-Naive Patients With Advanced Clear Cell Renal Cell Carcinoma (HCRN GU16-260-Cohort A) (2022) (11)
- Detection of concurrent/recurrent non-Hodgkin's lymphoma in effusions by PCR. (1999) (11)
- Papular clear cell hyperplasia of the eccrine duct in a diabetic (1996) (11)
- Mechanisms of acquired resistance to rapalogs in metastatic renal cell carcinoma (2018) (11)
- 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one (2016) (10)
- Identification of ALK Gene Alterations in Urothelial Carcinoma (2014) (10)
- Transgenic Expression of Polyomavirus Middle T Antigen in the Mouse Prostate Gives Rise to Carcinoma (2011) (10)
- Autochthonous tumors driven by Rb1 loss have an ongoing requirement for the RBP2 histone demethylase (2018) (10)
- Pdl-1/pdl-3 (programmed death ligand-1/3) tissue expression and response to treatment with IL2 and antiangiogenic therapies. (2013) (10)
- Mutations and Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma (2019) (10)
- Paraganglioma of the cauda equina. Case report with 33-month recurrence free follow-up and review of the literature. (1999) (10)
- Array-based comparative genomic hybridization (CGH) identifies chromosomal imbalances between Interleukin-2 complete and non-responders (2008) (10)
- Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma. (2016) (10)
- Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (2021) (10)
- Detection of TCR-gamma gene rearrangements in early mycosis fungoides by non-radioactive PCR-SSCP. (2000) (9)
- FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma (2016) (9)
- Minimally differentiated acute myeloid leukaemia revealed by specific cutaneous lesions (1996) (9)
- Allelic imbalance reveals widespread germline-somatic regulatory differences and prioritizes risk loci in Renal Cell Carcinoma (2019) (9)
- Integrative Clinical and Molecular Characterization of Translocation Renal Cell Carcinoma (2021) (8)
- Renal-cell carcinoma: a step closer to a new classification. (2013) (8)
- HIF-2α drives an intrinsic vulnerability to ferroptosis in clear cell renal cell carcinoma (2018) (8)
- Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial. (2020) (8)
- PD-L1 expression in mononuclear cells and not in tumor cells, correlated with prognosis in metastatic urothelial carcinoma. (2014) (8)
- Impact of immune checkpoint protein expression in tumor cells and tumor infiltrating CD8+ T cells on clinical benefit from PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC). (2017) (8)
- Association of gene expression with clinical outcomes in patients with renal cell carcinoma treated with pembrolizumab in KEYNOTE-427. (2020) (7)
- Cell Kinetic Studies Fail to Identify Sequentially Proliferating Progenitors as the Major Source of Epithelial Renewal in the Adult Murine Prostate (2015) (7)
- Erratum: High-throughput oncogene mutation profiling in human cancer (Nature Genetics (2007) 39, (347-351)) (2007) (7)
- Efficacy of immune checkpoint inhibitors (ICI) and genomic characterization of sarcomatoid and/or rhabdoid (S/R) metastatic renal cell carcinoma (mRCC). (2019) (7)
- Anti-CAIX BBζ CAR4/8 T cells exhibit superior efficacy in a ccRCC mouse model (2021) (7)
- Erratum: Corrigendum: High-throughput oncogene mutation profiling in human cancer (2007) (7)
- Blood Levels of Carbonic Anhydrase 9 Correlate with Clear Cell Renal Cell Carcinoma Activity (2009) (7)
- Plasticity in the Absence of NOTCH Uncovers a RUNX2-Dependent Pathway in Small Cell Lung Cancer (2021) (7)
- Corrigendum: Essential roles of PI(3)K–p110β in cell growth, metabolism and tumorigenesis (2016) (6)
- Transforming the Perioperative Treatment Paradigm in Non-Metastatic RCC—A Possible Path Forward (2017) (6)
- Killer immunoglobulin-like receptor (KIR) and KIR–ligand genotype do not correlate with clinical outcome of renal cell carcinoma patients receiving high-dose IL2 (2016) (6)
- Alterations in key clear cell renal cell carcinoma (RCC) genes to refine patient prognosis. (2018) (6)
- PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) versus observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). (2019) (6)
- Association of polybromo-associated BAF (PBAF) complex mutations with overall survival (OS) in cancer patients (pts) treated with checkpoint inhibitors (ICIs). (2019) (6)
- Association of human endogenous retrovirus (hERV) expression with clinical efficacy of PD-1 blockade in metastatic clear cell renal cell carcinoma (mccRCC). (2019) (6)
- Pharmacogenetics as predictor of sunitinib and mTOR inhibitors toxicity in patients with metastatic renal cell carcinoma (mRCC). (2013) (5)
- Abstract LB-313: ALK1-Fc inhibits tumor growth in a VEGF pathway resistance model of renal cell carcinoma (2012) (5)
- SAVOIR: A phase III study of savolitinib versus sunitinib in pts with MET-driven papillary renal cell carcinoma (PRCC). (2020) (5)
- Inhibition of ALK 1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma (2016) (5)
- Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced clear cell renal cell (HCRN GU16-260-Cohort A): Final report. (2022) (5)
- PD-L1 expression in non-clear cell renal cell carcinoma and benign kidney tumors. (2014) (5)
- Abstract LB-369: Sphingosine-1-phosphate (S1P) as a novel target in renal cancer (RCC) (2010) (5)
- A phase II trial of sunitinib and gemcitabine in sarcomatoid and/or poor-risk patients with metastatic renal cell carcinoma. (2015) (5)
- The impact of BMI on outcomes of patients with metastatic renal cell carcinoma treated with targeted therapy: An external validation data set and analysis of underlying biology from The Cancer Genome Atlas. (2015) (4)
- Phosphorylation of ETS 1 by Src Family Kinases Prevents Its Recognition by the COP 1 Tumor Suppressor (2014) (4)
- Loss-of-function of PBRM1 to predict response to anti-PD-1/PD-L1 therapy in metastatic renal cell carcinoma. (2017) (4)
- Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B). (2021) (4)
- MET status and treatment outcomes in papillary renal cell carcinoma (PRCC): Pooled analysis of historical data. (2020) (4)
- Biomarkers of Angiogenesis and Clinical Outcomes to Cabozantinib and Everolimus in Patients with Metastatic Renal Cell Carcinoma from the Phase III METEOR Trial. (2021) (4)
- Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up. (2022) (4)
- Comprehensive Genomic Profiling of Metastatic Tumors in a Phase 2 Biomarker Study of Everolimus in Advanced Renal Cell Carcinoma (2018) (4)
- Vulnerabilities of PTEN – TP 53-Defi cient Prostate Cancers to Compound PARP – PI 3 K Inhibition (2019) (4)
- Absence of HHV-8 DNA sequences in malignant mesothelioma. (1998) (4)
- Transcriptomic Correlates of Tumor Cell PD-L1 Expression and Response to Nivolumab Monotherapy in Metastatic Clear Cell Renal Cell Carcinoma. (2022) (4)
- Association of somatic ERCC2 mutations with cisplatin sensitivity in muscle-invasive urothelial carcinoma. (2014) (4)
- Tissue Biomarkers in Renal Cell Carcinoma: Intermediate Endpoints in the Selection of Targeted Agents for RCC (2012) (4)
- Longitudinal Molecular Profiling of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma (2022) (4)
- Sensitivity of VHL mutant kidney cancers to HIF2 inhibitors does not require an intact p53 pathway (2022) (4)
- A novel direct activator of AMPK inhibits prostate cancer growth by blocking lipogenesis (2014) (3)
- Evolution of circulating tumor DNA (ctDNA) profile from first-line (1L) to second-line (2L) therapy in metastatic renal cell carcinoma (mRCC). (2017) (3)
- Optimized management of nivolumab (NIVO) and ipilimumab (IPI) in advanced renal cell carcinoma (OMNIVORE): A response-based phase II study. (2018) (3)
- PROSPER: A phase III randomized study comparing perioperative nivolumab (nivo) vs. observation in patients with localized renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN 8143). (2019) (3)
- Identification of a novel urothelial carcinoma (UC) biomarker of lethality. (2011) (3)
- Activating genomic mutations in the mTOR pathway to predict responses to everolimus and temsirolimus in patients with metastatic renal cell carcinoma (mRCC): Results from a large multi-institutional cohort. (2015) (3)
- BRCA1/Trp53 heterozygosity and replication stress drive esophageal cancer development in a mouse model (2021) (3)
- Prognostic and predictive values of carbonic anhydrase IX (CAIX) and pathologic features in patients with metastatic clear cell renal cell carcinoma receiving targeted therapy. (2009) (3)
- DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA (2021) (3)
- Phase II study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy in patients with muscle-invasive urothelial cancer (MI-UC): Pathologic and radiologic response, serum tumor markers, and DNA excision repair pathway biomarkers in relation to disease- (2013) (3)
- Obesity in Relation to Renal Cell Carcinoma Incidence and Survival in Three Prospective Studies. (2022) (3)
- Differential expression of c-Met between primary and metastatic sites in clear-cell renal cell carcinoma (ccRCC) and its association with PD-L1 expression. (2017) (2)
- Do genetic polymorphisms predict risk of recurrence in patients with localized renal cell carcinoma? Results from a cohort study. (2011) (2)
- Abstract 5497: Cabozantinib eradicatesde novocastrate-resistant PTEN/p53 deficient murine prostate cancer via activation of neutrophil-mediated anti-tumor innate immunity (2015) (2)
- Blocking PI3K p110β Attenuates Development of PTEN-Deficient Castration-Resistant Prostate Cancer. (2022) (2)
- Abstract A18: Genomic and neoantigen evolution and resistance to immune checkpoint blockade in metastatic renal cell carcinoma (2017) (2)
- Carbonic anhydrase IX (CA IX) and pathologic features as predictors of outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving VEGF-targeted therapy (2008) (2)
- Epigenomic charting and functional annotation of risk loci in renal cell carcinoma (2023) (2)
- Biomarker-Based Phase II Study of Sapanisertib (TAK-228): An mTORC1/2 Inhibitor in Patients With Refractory Metastatic Renal Cell Carcinoma (2022) (2)
- Evaluation of predictive biomarkers for nivolumab in metastatic clear cell renal cell carcinoma (mccRCC) using RECIST and immune-related (IR) RECIST. (2018) (2)
- Erratum: A working group classification of focal prostate atrophy lesions (American Journal of Surgical Pathology (2006) 30 (1281-1291)) (2006) (2)
- Abstract 4541:METgene copy number gains evaluated by NGS is more predictive than other methods to enrich for papillary RCC patients sensitive to savolitinib, a selective MET inhibitor (2018) (2)
- Abstract 5080: Inhibiting the ALK1/BMP9 signaling pathway with dalantercept as an antiangiogenic therapy. (2013) (2)
- Ultrasensitive detection of TCR hypervariable region in solid-tissue RNA-seq data (2016) (2)
- A phase II multicenter study of neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin (ddMVAC) chemotherapy with pegfilgrastim support in patients (pts) muscle-invasive urothelial cancer (MIUC): Safety, pathologic, radiologic, and molecular correlates. (2013) (2)
- 39 – Molecular Abnormalities in Kidney Cancer (2015) (2)
- Cell-free tumor DNA and TERT promoter mutations in bladder cancer. (2017) (2)
- Postoperative liver transplant monitoring with fine-needle aspiration biopsy. (1989) (2)
- Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (2022) (2)
- Programmed death-ligand 1 (PD-L1) expression in cured and not cured testicular and other germ cell tumors (GCT). (2016) (2)
- Circulating immune cell populations and cytokines in patients with metastatic variant histology renal cell carcinoma (vRCC) treated with atezolizumab plus bevacizumab (AB): Dynamic changes on therapy and association with outcomes from a phase II trial. (2020) (1)
- Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade. (2020) (1)
- PI3KCA mutations in advanced urothelial carcinoma: A potential therapeutic target? (2012) (1)
- Carbonic Anyhydrase IX (CAIX) Expression Does Not Correlate with the Renal Cell Cancer (RCC) Patient Response to CCI-779 (2004) (1)
- CD73 expression in primary and metastatic renal cell carcinoma (RCC). (2018) (1)
- Metastatic penile carcinoma associated with convergent gain-of-function mutations in NOTCH1 (2018) (1)
- The impact of PBRM1 and BAP1 expression on outcomes of patients with metastatic renal cell carcinoma (mRCC) treated with VEGF-targeted therapy (TT). (2016) (1)
- Human Prostate Epithelial Cells Androgen-Induced Differentiation and Tumorigenicity of Updated (2004) (1)
- Author Correction: Pan-cancer analysis of whole genomes (2023) (1)
- Pathologic scoring of pre-treatment H&E biopsies predicts overall survival in patients with metastatic clear cell renal cell carcinoma receiving nivolumab monotherapy (2019) (1)
- Abstract 1021: HDM2 inhibition augments the antitumor and antiangiogenic effects of sunitinib by suppressing sunitinib-induced SDF-1 expression and tumor recruitment of CD11b/Gr1+ MDSC in RCC xenografts (2012) (1)
- Abstract #153: Cox-2 inhibition delays resistance to sunitinib in RCC xenograft models (2009) (1)
- Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC). (2015) (1)
- Genomic profiling of nephrectomy and metastatic sites in patients with advanced clear cell renal cell carcinoma (RCC). (2017) (1)
- Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer (2020) (1)
- Genomic alterations to refine prognostication of patients with metastatic renal cell carcinoma. (2018) (1)
- The association between overexpression of skp2 and the risk of recurrence following prostatectomy (2008) (1)
- The p27 ubiquitin ligase skp2 is overexpressed in breast cancer (2001) (1)
- Gene Expression Patterns Associated with Renal Cancer (RCC) Response and Resistance to IL-2-Based Therapy (2004) (1)
- Supplementary Material 10 (2014) (1)
- T-cell receptor (TCR) repertoire in metastatic renal cell carcinoma (RCC) patients treated with first-line vascular endothelial growth factor receptor blockade. (2016) (1)
- Association of higher PD-L1 expression in tumor cells of metastatic ccRCC lesions with worse overall survival. (2016) (1)
- Association of inherited genetic variation with clinical outcome in patients with advanced renal cell carcinoma treated with mTOR inhibition. (2012) (1)
- TMOD-14. CREATION OF A GENETICALLY ENGINEERED MOUSE MODEL OF ANAPLASTIC ASTROCYTOMA DRIVEN BY THE IDH1-R132H ONCOGENE (2020) (1)
- Identification of De Novo Pyrimidine Synthesis as a Targetable Vulnerability in a Novel IDH1 Mutant Engineered Astrocytoma Model. (2021) (1)
- Regulation of neuroendocrine plasticity by the RNA-binding protein ZFP36L1 (2021) (1)
- Differential expression of PD-L1 expression in high grade T1 (HGT1) v. muscle invasive urothelial carcinoma (MIUC) and its prognostic implications. (2016) (1)
- Inhibition of tumor growth in a VEGFR TKI-resistant model of renal cell carcinoma using dalantercept combined with sunitinib. (2013) (1)
- Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. (2016) (1)
- Abstract 5122: Identification of PD-L1 expression on circulating tumor cells as a prognostic indicator in prospective clinical trial, OMNIVORE (2022) (0)
- Phase II study of nivolumab and salvage nivolumab/ipilimumab in treatment-naïve patients with advanced non-clear cell renal cell carcinoma (HCRN GU16-260-Cohort B) (2023) (0)
- Cell Reports Resource The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma (2018) (0)
- Genetic polymorphisms’ influence in outcome of metastatic renal cell cancer patients treated with VEGF-targeted agents. (2012) (0)
- Aurora kinase-mTOR signaling in sarcomatoid mRCC 1 RNA-seq Reveals Aurora Kinase Driven-mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma (2014) (0)
- Prognostic value of genomic signatures in metastatic Clear Cell Renal Cell Carcinoma (mRCC) using The Cancer Genome Atlas (TCGA) data. (2015) (0)
- In Reply (2017) (0)
- Abstract 886: Fine-tuned CAIX targeted CAR-T cells exhibit superior efficacy and mitigate on-target off-tumor side effects (2023) (0)
- 193 High cytoplasmic and low nuclear expression of HIF-2α are associated with worse cancer specific survival (CSS) in clear cell renal cell carcinoma (2013) (0)
- Abstract 381: Enhancement of efficacy of sorafenib and sunitinib with the HDM2 antagonist MI-319 in RCC tumor xenografts (2010) (0)
- Author Correction: The evolutionary history of 2,658 cancers (2023) (0)
- PD-L1 status and clinical outcomes to cabozantinib, sunitinib and everolimus in patients with metastatic clear-cell RCC treated on CABOSUN and METEOR clinical trials. (2018) (0)
- Mitochondrial transporter expression patterns distinguish tumor from normal tissue and identify cancer subtypes with different survival and metabolism (2022) (0)
- Integrated analysis of metastatic disease in clear cell renal cell carcinoma: A collaborative TCGA analysis. (2014) (0)
- Abstract C112: Cabozantinib eradicates advanced murine prostate cancer by activating anti-tumor innate immunity (2015) (0)
- Abstract 2814: Anti-CAIX Immune Restoring (IR) CAR-T cells display superior antitumor activity and reverse immunosuppressive TME in a humanized ccRCC orthotopic mouse model (2022) (0)
- Investigating the association of cytoplasmic and nuclear HIF-2 expression with cancer specific survival (CSS) in clear cell renal cell carcinoma. (2013) (0)
- Prognostic significance of CD73 expression in localized renal cell carcinoma (RCC). (2019) (0)
- The Basal Cell Marker p63 and Prostate Stem Cells (2002) (0)
- Abstract 4979: Cabozantinib eradicates advanced murine prostate cancer by activating neutrophil-mediated anti-tumor innate immunity (2016) (0)
- Comparison VEGF-pathway elements and EMT markers in patients with sarcomatoid metastatic renal cell carcinoma and risk-matched controls. (2014) (0)
- Abstract #2749: In vitro and in vivo efficacy of the dual PI3-kinase/mTOR inhibitor NVP-BEZ235 in renal cell carcinoma (RCC) (2009) (0)
- Abstract NG05: Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53 null tumors (2014) (0)
- 27A Targeting the PI3K/mTOR pathway in genetically engineered mouse models of advanced prostate cancer (2010) (0)
- CANCER STEM CELL FEATURE CAN INDUCE RESISTANCE TO MTOR INHIBITORS VIA THE NOTCH PATHWAY IN RENAL CELL CARCINOMAS: MP88‐14 (2018) (0)
- Abstract NG13: Metabolomic adaptations and correlates of survival to immune checkpoint blockade (2020) (0)
- Abstract 1491: Notch1 Inhibition Interferes with Differentiation of Glomerular Progenitor Cells into Podocytes (2008) (0)
- Somatic ERCC2 Mutations Confer Cisplatin Sensitivity in Muscle-Invasive Urothelial Cancer (2014) (0)
- A phase II biomarker trial of everolimus in patients with advanced renal cell carcinoma (08-313). (2014) (0)
- Genomic and clinical determinants of recurrence in localized clear cell renal cell carcinoma (ccRCC). (2019) (0)
- Abstract LB-418: Targeting the PI3K/mTOR pathway in genetically engineered mouse models of prostate cancer (2011) (0)
- MP11-14 QUANTITATIVE PERFUSION MEASUREMENTS IN RENAL MASSES WITH ASL AND DCE MRI AT 3T CORRELATE WITH MICROVASCULAR DENSITY AT HISTOPATHOLOGY (2015) (0)
- 872POutcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib (c) vs everolimus (e) in advanced renal cell carcinoma (rcc) (2017) (0)
- Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma (2018) (0)
- Assessment of a cell-line-derived HIF1α gene signature in tumor tissue from a metastatic renal cell carcinoma (RCC) trial of pazopanib. (2012) (0)
- Spatially aware deep learning reveals tumor heterogeneity patterns that encode distinct kidney cancer states (2023) (0)
- Genomics RNA-seq Reveals Aurora Kinase – Driven mTOR Pathway Activation in Patients with Sarcomatoid Metastatic Renal Cell Carcinoma (2015) (0)
- Abstract LB-365: Effective use of PI3K/MTOR and MEK inhibitors prior to hormone ablative therapy in PTEN-loss driven murine prostate cancer (2012) (0)
- Initial results of a phase II study of nivolumab(N) and ipilimumab(I) in genitourinary malignancies with neuroendocrine differentiation. (2022) (0)
- Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma (UC). (2013) (0)
- Association of DNA repair factors with overall survival in advanced urothelial carcinoma treated with platinum-based chemotherapy. (2012) (0)
- Abstract 3179: Design and activity of 2ndgeneration, dual-targeted CAR T cell factories against ccRCC (2019) (0)
- Identification of ALK gene alterations in urothelial carcinoma (UC). (2011) (0)
- A phase II study of bevacizumab (Bev) and temsirolimus (Tem) in VEGF-refractory metastatic renal cell carcinoma (mRCC). (2014) (0)
- Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples (2020) (0)
- Comprehensive analyses of tumor immunity: implications for cancer immunotherapy (2016) (0)
- Correction for Emerling et al., Identification of CDCP1 as a hypoxia-inducible factor 2α (HIF-2α) target gene that is associated with survival in clear cell renal cell carcinoma patients (2021) (0)
- Deep sequencing of sarcomatoid renal cell carcinoma (sRCC) and identification of aurora kinases and mTOR as potential therapeutic targets. (2014) (0)
- OP-JNCI200067 1..10 (2020) (0)
- Author Correction: Patterns of somatic structural variation in human cancer genomes (2020) (0)
- Achieve clear cell renal cell carcinoma (CCRCC) cures through dual-targeted fine-tuned immune restoring (DFIR) CAR-T cell therapy (2021) (0)
- Correction to: Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (2021) (0)
- 1071 POOR PROGNOSIS AND ADVANCED CLINICOPATHOLOGICAL FEATURES OF CLEAR CELL RENAL CELL CARCINOMA (CCRCC) ARE ASSOCIATED WITH CYTOPLASMIC SUBCELLULAR LOCALIZATION OF HIF-2α (2013) (0)
- Technical Advance Detection of Clonal T-Cell Receptor g Gene Rearrangements in Paraffin-Embedded Tissue by Polymerase Chain Reaction and Nonradioactive Single-Strand Conformational Polymorphism Analysis (1998) (0)
- Response to savolitinib (AZD6094/HMPL-504, a potent and selective MET inhibitor) in a papillary renal cell carcinoma patient harbouring a novel MET activating mutation (2016) (0)
- Associations of Fc gamma receptor (FcgR2a, FcgR3a and FcgR2c) genotype with outcome in metastatic renal cell carcinoma (mRCC) patients receiving high dose interleukin 2 (HD-IL2) (2015) (0)
- External validation of somatic copy number alteration (SCNA) at chromosome 1q23.3 in advanced urothelial carcinoma (UC). (2012) (0)
- Immortalized Mammary Epithelial Cell Line Growth Factor Requirements and Basal Phenotype of an Updated (2001) (0)
- Abstract 1608: Angiopoietin 2 is elevated in patients with RCC, and Ang2 inhibition improves antiantiogenic activity of sunitinib in a mouse model of RCC. (2013) (0)
- An aberrant SREBP-dependent lipogenic program promotes metastatic prostate cancer (2018) (0)
- Examination of resistance to nivolumab monotherapy through single-cell analysis of tumors from patients enrolled in the HCRN GU16-260 study of nivolumab monotherapy. (2023) (0)
- Abstract 62: Development of dual-targeted fine-tuned immune restoring (DFIR) CAR T cell therapy for clear cell renal cell carcinoma (ccRCC) (2021) (0)
- Arterial Spin Labeling Perfusion Measurements Reflect Histologic Microvessel Density in an Experimental Model of Tumor Response and Eventual Resistance to Antiangiogenic Therapy (2011) (0)
- Carbonic anhydrase IX (CAIX) as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma (mccRCC) in patients (pts) receiving sorafenib: Analysis of a randomized controlled trial (TARGET). (2012) (0)
- Corrigendum: Loss of LDAH associated with prostate cancer and hearing loss. (2019) (0)
- Molecular Cancer apeutics linical Development al Cancer Resistance to Antiangiogenic Therapy Is Ther ayed by Restoration of Angiostatic Signaling (2010) (0)
- compound PARP / PI 3 K inhibition Vulnerabilities of PTEN-p 53-deficient prostate cancers to (2014) (0)
- Abstract A31: Merlin loss as a biomarker for defactinib (VS-6063) sensitivity: High frequency in malignant mesothelioma tumors. (2013) (0)
- Evaluation of RNA-sequencing (RNA-seq) signatures with pembrolizumab (pembro) in patients (pts) with renal cell carcinoma (RCC) from KEYNOTE-427 cohort A. (2020) (0)
- Editor's Note: The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared with Rapamycin in Renal Cell Carcinoma (2019) (0)
- Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma (2023) (0)
- A model combining clinical and genomic factors to predict response to PD-1/PD-L1 blockade in advanced urothelial carcinoma (2019) (0)
- 295 Affinity fine-tuning anti-CAIX CAR-T cells mitigate on-target off-tumor side effects (2022) (0)
- Adult Prostate Epithelium Renewal, Stem Cells and Cancer (2009) (0)
- Rapid immunostaining of frozen sections: a tool for laser capture microdissection and quantitative RT-PCR (2001) (0)
- Association of DNA repair factors with overall survival in advanced urothelial carcinoma treated with platinum-based chemotherapy. (2012) (0)
- Abstract 3866: Targeting AXL can effectively inhibit c-Met-induced therapeutic resistance in renal cancer (2023) (0)
- Abstract 2108: Notch1-Dependent Cardiomyogenesis is an Essential Component of Postnatal Cardiac Growth (2009) (0)
- Aleukemic granulocytic sarcoma (1998) (0)
- Impact of MET status on treatment outcomes in papillary renal cell carcinoma: A pooled analysis of historical data. (2022) (0)
- Abstract 3818: Notch1 Receptor Blockade Results in Dilated Cardiomyopathy in the Neonatal Mouse Heart (2008) (0)
- p63 in Development and Maintenance of the Prostate Epithelium (2008) (0)
- A GPX4-dependent cancer cell state underlies the clear-cell morphology and confers sensitivity to ferroptosis (2019) (0)
- 1 Renal cell carcinoma 1 2 (2017) (0)
- Human anti-CAIX antibodies mediate immune cell inhibition of renal cell carcinoma in vitro and in a humanized mouse model in vivo (2015) (0)
- MP23-09 INTEGRATED ANALYSIS OF METASTATIC DISEASE IN CLEAR CELL RENAL CELL CARCINOMA: A COLLABORATIVE TCGA ANALYSIS (2014) (0)
- Author Correction: A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer (2020) (0)
- Androgen-dependent regulation of Her-2/neu in prostate cancer cells. (2006) (0)
- Assessment of a cell-line-derived HIF1α gene signature in tumor tissue from a metastatic renal cell carcinoma (RCC) trial of pazopanib. (2012) (0)
- Supplementary Material 8 (2013) (0)
- Author Correction: Inferring structural variant cancer cell fraction (2022) (0)
- Abstract 6606: Develop dual-targeted CAR-T cells to achieve RCC cures (2020) (0)
- The association of tumor infiltrating CD8+ and Foxp3+ cells with overall response rate (ORR) in metastatic renal cell carcinoma (mRCC) patients treated with high-dose aldesleukin (HD IL-2). (2017) (0)
- Interplay of somatic alterations and immune infiltration modulates response to PD-1 blockade in advanced clear cell renal cell carcinoma (2020) (0)
- Outcomes based on plasma biomarkers in METEOR, a randomized phase 3 trial of cabozantinib vs everolimus in advanced renal cell carcinoma (2021) (0)
- Diagnostic Criteria for Primary Cutaneous Marginal Zone B-Cell Lymphomas: 20 (1997) (0)
- Abstract PR2: Identification of luminal breast cancers that establish a tumor supportive macroenvironment defined by proangiogenic platelets and bone marrow derived cells (2013) (0)
- Abstract 5774: Small cell lung cancer subtype plasticity is regulated by KDM6A (2023) (0)
- Anatomic Pathology / Carbonic Anhydrase IX in Renal Tumors (2010) (0)
- Statin use and risk of renal cell carcinoma in three prospective cohort studies. (2018) (0)
- The UTX Tumor Suppressor Directly Senses Oxygen to Control Chromatin and Cell Fate (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Sabina Signoretti?
Sabina Signoretti is affiliated with the following schools:
